Canada Markets close in 1 hr 15 mins

Corvus Pharmaceuticals, Inc. (CRVS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.3500-0.0600 (-1.76%)
As of 02:44PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close3.4100
Open3.5900
Bid3.3500 x 800
Ask3.3600 x 1000
Day's Range3.3100 - 3.6400
52 Week Range1.8600 - 9.5400
Volume920,761
Avg. Volume8,747,441
Market Cap128.337M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-0.1770
Earnings DateNov. 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.13
  • GlobeNewswire

    Corvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    Figure HNSCC AND NSCLC AT MUPADOLIMAB DOSES ≥ 12 MG/KG Results in patients with relapsed refractory NSCLC and head and neck cancer demonstrate tumor reduction in patients treated with mupadolimab mono and combination therapy Corvus enrolling additional patients with these cancers in a Phase 1b/2 trial, with additional data anticipated in 2022 Corvus to host conference call and webcast today at 9:00 a.m. ET / 6:00 a.m. PT BURLINGAME, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceutical

  • GlobeNewswire

    Corvus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

    BURLINGAME, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies London Healthcare Conference, which is taking place November 16-19, 2021. The Company will conduct one-on-one meetings with investors at this conference and a pre-recorded corporate overview presentation by Richard A. Miller, M.D., president and chief executive officer of Corvus, will be available to p

  • GlobeNewswire

    Corvus Pharmaceuticals to Present Updated Mupadolimab (Anti-CD73) Data at 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    Company to host conference and webcast on November 12, 2021 at 9:00 am ET / 6:00 am PTBURLINGAME, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present data from its Phase 1/1b trial of mupadolimab at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place on November 10-14, 2021. The updated data from the mupadolimab study will be presented in a poster at SI